Imugene Ltd announced a second complete response in its Phase 1b azer-cel trial targeting patients with mantle cell lymphoma (MCL) who had failed prior BTKi therapy. This follows the first complete response reported just a day earlier in the same trial cohort. The trial tests azer-cel, an off-the-shelf CAR T cell therapy designed to treat blood cancers, aiming to restore or enhance treatment efficacy in patients resistant to BTK inhibitors. With limited options for these patients, the positive early results highlight a promising clinical and commercial opportunity. The trial is ongoing across multiple sites in the US and Australia, with further data updates expected.
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
LithiumBank Resources Corp. has appointed Logan R. Harris as Vice President of Project Development to lead the advancement of its Boardwalk Lithium Brine Project in Alberta. Harris brings over 15 years of experience in engineering and project develop...
